Survival prognosis factors in multiple myeloma

##plugins.themes.academic_pro.article.sidebar##

Published Dec 30, 2014
Download
pdf
Vol. 92 No. 6 (2014): Issue Jun 2014

##plugins.themes.academic_pro.article.main##

M. Younes
H. Hachfi
F. Hammouda
K. Younes
S. Ben Hammouda
M. Jguirim
S. Zrour
I. Béjia
M. Touzi
N. Bergaoui

Abstract

Background: Outcome in multiple myeloma (MM) is very heterogeneous in survival and therapeutic response, constantly fatale despite her therapy progress.

aim: To determine the prognostic factors and survival in MM.

methods: We carried out a transversal study of 100 patients in the rheumatology department of hospital Monastir between 1991 and 2010. In each case we determinate the survival delay and also the clinical, laboratory, radiological data at diagnosis and therapeutic response.

results: The mean age was 64.4 years and sex ratio H/F=1.27. MM is IgG type in 57%, IgA in 28% and light chain in 11% of cases. The survival mean is 34 months and the survival median is 26 months. Univariate analysis showed five prognostic factors: age (p = 0.016), anaemia (p=0.033), β2 microglobulin ( p < 0.0001) , CRP (p = 0.0001), albumin (p = 0.002), LDH (p=0.001), plasmocyte proliferation rate (p=0.003) and rapidly therapeutic response (p <0.001). β2 microgrobulin-CRP classification and the international staging system (ISS) presented a high prognosis signification (p < 0.0001). Multivariate analysis demonstrated two prognostic factors: β2 microglobulin and CRP.

Conclusions: Our study showed that MM presented many prognostic factors, which easily realised in daly practice. These prognostic factors are essentially to evaluate prognosis and select patients for appropriate therapeutic indication. β2 microgrobulin- CRP classification and the international staging system (ISS) are more predictive than Durie Salmon classification in MM survival.

Keywords:

Multiple myeloma, prognostic factors, classification, survival

##plugins.themes.academic_pro.article.details##

References

  1. Paule B. Facteurs pronostiques du myélome multiple. Ann Med Interne (Paris) 1997;148:534-41.
  2. Bosch F, Blade J, Lopez-Guillermo A Et Al. Impact of response to treatment on survival in multiple myeloma : results in a series of 243 patients. Br J Haematol 1994; 88: 117-21.
  3. Child Ja, Morgan Gj, Davies Fe Et Al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348:1875-83.
  4. Bauduer F, Troussard X, Delmer A. Facteurs pronostiques du myélome multiple : revue de la littérature. Bull Cancer 1993 ; 80 : 1035-42.
  5. San Miguel Jf, Garcia-Sanz R. Prognostic features of multiple myeloma. Best Pract Res Clin Haematol. 2005; 18:569-83.
  6. Barlogie B, Bolejack V, Schell M, Crowley J. Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Ann Hematol. 2011; 90:423-8.
  7. Durie Bgm, Stock-Novack D, Salmon Se Et Al. Prognostic value of pre-treatment serum beta2- microglobulin in myeloma: a Southwest Oncology Group Study. Blood 1990; 75:823-30.
  8. Terpos E, Berenson J, Cook Rj, Lipton A, Coleman Re. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia. 2010; 24:1043-9.
  9. Diem H, Fateh-Moghadam A, Lamrez R. Prognostic factors in multiple myeloma: role of beta -2 microglobulin and thymidine kinase. Clin Investing 1993; 71: 918-23.
  10. wig H, Bolejack V, Crowley J Et Al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010; 28:1599-605.
  11. Avet-Loiseau H, Daviet A, Sauner S, Bataille R. Intergroupe francophone du myélome. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 2000; 111 : 1116-7.
  12. Spica I, Cieslar P, Prochazka B Et Al .Prognostic and markers of activity in multiple myeloma (results of the cooperative group for diagnosis and treatment of multiple myeloma). Cas Lek Sesk 2000; 139: 208-12.
  13. Desikan Kr, Barlogie B, Sawyer J Et Al. Results of high dose therapy for 1000 patients with multiple myeloma / durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95:4008-10.
  14. Königsberg R, Zojer N, Ackermann J Et AL. Predictive role of interphase cytogenetics for survival of patints with multiple myeloma. J Clin Oncol 2000; 18:804-12.
  15. Greipp Pr, San Miguel J, Durie Bg Et Al. International Staging System for multiple myeloma. J Clin Oncol 2005; 23:3412-20.
  16. DURIE BGM, SALMON SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-54.
  17. Bataille R, Boccadoro M, Klein B Et Al. C-reactive protein and β2-microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733-7.
  18. Palmer M, Belch A, Brox L, Pollock E, Koch M. Are the current criteria for response useful in the management of multiple myeloma? J Clin Oncol. 1987;5(9):1373-7.
  19. Fermand Jp, Ravaud P, Katsahian S Et Al. High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma: results of a randomized trial in 190 patients 55 to 65 years. Blood 1999; 94: 396-7.
  20. Child Ja, Morgan Gj, Davies Fe Et Al. High dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-83.
  21. Chombart B, Gagneux-Lemoussu L, Eschard Jp Et Al. Facteurs pronostiques du myélome utilisables en pratique courante : suivi sur dix ans de 148 malades âgés de plus de 55 ans. Rev Rhum 2005 ; 72 : 1299-1305.
  22. Rajkumar Sv, Greipp Pr. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am 1999; 13:1295-314.
  23. Franco M, Fuzibet Jg, Cassuto Jp, Pesce A, Ziegler G, Dujardin P. Myélome multiple avec 5 ans de survie. Étude des facteurs pronostiques initiaux. Place de la bêta2-microglobuline. Rev Rhum [Ed Fr] 1985; 52:619-23.
  24. Ludwig H, Fritz E, Friedl HP. Epidemiologic and age-dependent date on multiple myeloma in austria. J.Nath Cancer Inst 1982; 68:729-33.
  25. Eschard Jp, Pignon B. Facteurs pronostiques et surveillance du myélome. Rev Med Interne 1992; 13:273-7.
  26. Ben Abid H, Meddeb B, Ben Abdallah M, Et Al. Long-term survival and prognostic factors in multiple myeloma treated with conventional chemotherapy. Report of 109 cases. Tunis Med. 2000; 78:705-12.
  27. Bataille R, Grenier J, Sany J. Beta2-microglobulin in myeloma: optimal use for staining, prognosis, and treatment. prospective study of 160 patients. Blood 1984; 63:468-76.
  28. Kaltwasser P, Sauger F, Le Loet X, Pasquis P, Monconduit M, Deshayes P. Intérêt du dosage de la bêta2-microglobuline dans la surveillance des myélomes.A propos de 290 dosages. Rev Rhum 1982; 49:359-63.
  29. Pulkki K, Pelliniemi Tt, Rajamäki A, Tienhaara A, Laakso M, Lahtinen R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br J Haematol 1996; 92:370-4.
  30. Kádár K, Wolf K, Tábori J, Karádi I, Várkonyi J. The Albumin and Monoclonal Protein Ratio as Prognostic Marker for Multiple Myeloma in the Era of Novel Agents. Pathol Oncol Res. 2012; 18: 557-61. 2003; 122: 441-450.
  31. Fonseca R, San Miguel J. Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am. 2007; 21:1115-40. Haematol. 2010; 85:114-9.
  32. Jacobson J, Hussein M, Barlogie B, Durie Bgm, Crowley J. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003; 122: 441-450.
  33. Terpos E, Katodritou E, Roussou M Et Al. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol. 2010; 85:114-9. Lymphoma. 2012; 53:920-927.
  34. Knudsen Lm, Hjorth M, Hippe E. renal failure in multiple myeloma: reversibility and impact on the prognosis. Eur J Haematol 2000; 65: 175-81.
  35. Nemec P, Zemanova Z, Kuglik P Et Al. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma. 2012; 53:920-927. for patients receiving high-dose therapy. Blood 2001; 97: 1566-71.
  36. Shaughnessy J, Tian E, Sawyer J Et Al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000;96:1505-11. hybridization. Blood 2001; 95: 1925-30.
  37. Facon T, Avet-Loiseau H, Guillerm G Et Al. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-71.
  38. Zojer N, Königsberg R, Ackermann J Et AL. Deletion of 13q14 remains an independent prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2001; 95: 1925-30.
  39. Greipp Pr, Katzmann Ja, O'fallon Wm, Kyle RA. Value of β2- microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72: 219-23.
  40. Murakami H, Nemoto K, Sawamura M Et AL. Prognostic relevance of morphological classification in multiple myeloma. Acta Haematol 1992; 87:113-7.
  41. Al-Sahmani M, Trnavska I, Sevcikova S Et Al. Prognostic significance of morphological assessment of plasma cells in multiple myeloma. Neoplasma 2011; 58:554-60.
  42. Kyrtsonis Mc, Maltezas D, Tzenou T, Koulieris E, Bradwell AR. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol. 2009; 46:110-7.
  43. Bladé J, Rosiñol L, Cibeira MT. Prognostic factors for multiple myeloma in the era of novel agents. Ann Oncol. 2008;19 (Suppl 7):vii 117-20.